Ben Fidler - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Ben Fidler's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Ben Fidler
Verified
Senior Editor, BioPharma Dive
Virginia
Beats
adventure, solo travel, outdoors buying guides, lifestyle,Alaska travel, consumer goods, health fitness, soft adventure
Others not in covered section.
Content
By Ben Fidler Verified| BioPharma Dive Verified Bristol Myers Squibb on Monday said its drug Camzyos failed a Phase 3 trial in people with a progressive heart condition, closing off an opportunity to expand use of a medicine it sees as a future blockbuster. According to Bristol Myers, Camzyos missed the dual main goals of a study focused on the non-obstructive form of “HCM,” or hypertrophic cardiomyopathy. It failed to meaningfully improve peak oxygen consumption as well as scores on an assessment of heart health.
By Ben Fidler Verified| BioPharma Dive Verified An experimental gene editing treatment from Verve Therapeutics appeared to safely lower cholesterol levels in a small clinical trial, giving the biotechnology company a chance to rebound from an earlier setback. Verve has been working on a one-time treatment that can prevent heart attacks for life by making a precise edit to a liver gene called PCSK9.
By Ben Fidler Verified| BioPharma Dive Verified Bristol Myers Squibb on Monday said its drug Camzyos failed a Phase 3 trial in people with a progressive heart condition, closing off an opportunity to expand use of a medicine it sees as a future blockbuster. According to Bristol Myers, Camzyos missed the dual main goals of a study focused on the non-obstructive form of “HCM,” or hypertrophic cardiomyopathy. It failed to meaningfully improve peak oxygen consumption as well as scores on an assessment of heart health.
Company Info
BioPharma Dive
Banking Dive is a prominent online publication dedicated to the banking industry. It offers in-depth journalism and analysis, providing valuable insights into the latest news, trends, and regulatory changes affecting the sector. As part of Industry Dive, which has merged with TechTarget's technology websites and Informa Tech, Banking Dive has expanded its editorial reach significantly. The platform features a variety of services, including detailed news coverage, a newsletter for subscribers, and deep dive articles that explore specific topics such as regulations and technology's role in banking. Banking Dive caters to professionals in the banking sector, including executives, policymakers, and financial analysts, delivering reliable information to help them navigate the evolving landscape of the industry.
Washington, District of Columbia, United States
+1 202-331-2480